Comprehensive Clinical Enzymology Study Notes: Creatine Kinase Isoenzymes, Diagnostics, and Assays
General Characteristics of Creatine Kinase
Enzyme Nomenclature and Classification:
- Common Name: Creatine Kinase (CK)
- Alternative / Common Abbreviation: Creatine Phosphokinase (CPK)
- Enzyme Commission Number: E.C.\n2.7.3.2
- Molecular Weight:
- Diagnostic Specificity: Moderate specificity
Biological Function and Catalytic Activity:
- Catalyzes the reversible phosphorylation of creatine by adenosine triphosphate (ATP).
- Primary role: Associated with ATP regeneration in contractile or transport systems.
- In muscle cells: Directly involved in the storage of high-energy creatine phosphate (phosphocreatine).
- Adenosine triphosphate (ATP) serves as the immediate source of energy during cellular work.
- Reversibility and pH Optimum:
- Forward Reaction (Phosphocreatine synthesis): Optimum pH
- Reverse Reaction (ATP regeneration): Optimum pH
- Reversible Chemical Reaction:
Physiological States:
- At Rest: Creatine is phosphorylated by ATP to form high-energy Phosphocreatine and ADP.
- At Work: Phosphocreatine transfers its high-energy phosphate group back to ADP to produce Creatine and ATP for cellular energy.
Pathophysiological Marker:
- When elevated in blood, CK indicates the destruction of muscle cells.
- Commonly associated with conditions such as muscle dystrophy or inflammation.
- The primary function of CK takes place in muscle tissue, where it drives the production of high-energy creatine phosphate.
Tissue Distribution and Structural Properties
Tissue Sources:
- Greatest Activity: Skeletal muscle (SM), Brain tissue (BT), and Heart muscle (HM).
- Smaller Quantities (Visceral Tissues): Bladder, placenta, gastrointestinal tract (GIT), thyroid, uterus, kidney, lung, prostate, spleen, and pancreas.
- Devoid of CK Activity: Liver tissue and erythrocytes (red blood cells) are completely devoid of CK activity.
Molecular Structure:
- Dimeric structure composed of two distinct subunits:
- B Subunit: Brain-type subunit
- M Subunit: Muscle-type subunit
- Subunit Mass: Each subunit has a molecular weight of approximately .
- Subcellular Localization: All cytosolic isoenzymes are located within the cell cytosol.
Isoenzymes and Electrophoretic Mobility
Standard Cytosolic Isoenzymes:
- CK-BB (CK1): Brain-type isoenzyme.
- Cytosolic distribution: Brain, prostate, gut, lung, bladder, uterus, placenta, and thyroid.
- CK-MB (CK2): Hybrid-type isoenzyme.
- Cytosolic distribution: Present in varying degrees in heart muscle ( of total CK activity in cardiac tissue) and to a minor degree in skeletal muscle.
- CK-MM (CK3): Muscle-type isoenzyme.
- Cytosolic distribution: Predominates in both skeletal muscle and cardiac muscle.
- Majority of cardiac muscle activity is attributed to CK-MM.
- Normal Serum Distribution: Represents approximately of circulating total CK in healthy individuals.
- Elevations in serum CK-MM indicate injury to cardiac or skeletal muscle.
Electrophoretic Migration Pattern:
- Migration is based on the charge and properties of protein particles towards the anode (+).
- CK-BB (CK1): Migrates fastest towards the anode.
- CK-MB (CK2): Intermediate electrophoretic mobility.
- CK-MM (CK3): Exhibits the slowest mobility, remaining closest to the cathode / point of origin.

Atypical Forms of Creatine Kinase
Macro-CK:
- Electrophoretic Mobility: Migrates to a position intermediate between CK-MM and CK-MB.
- Macro-CK Type 1:
- Complexes: CK-1 (CK-BB) associated with IgG, or CK-3 (CK-MM) associated with IgA.
- Macro-CK Type 2:
- Oligomeric complex of mitochondrial CK (CK-Mt).
- Epidemiology and Clinical Correlation:
- Serum incidence: Small incidence of approximately .
- No specific disease state is directly linked to its presence, though it appears to be age- and sex-related.
- Occurs most frequently in women over of age.
Mitochondrial CK (CK-Mi):
- Considered the 4th isoenzyme of CK.
- Localization: Bound to the exterior surface of the inner mitochondrial membranes of muscle, brain, and liver cells.
- Molecular Structure: Exists in serum as both a dimeric state and as oligomeric aggregates.
- Molecular Weight: .
- Electrophoretic Mobility: Migrates cathodic to CK-MM (from a cathodal point toward CK-MM); differs immunologically and electrophoretically from cytosolic forms.
- Prevalence and Clinical Significance:
- Serum incidence: .
- Absent in normal healthy serum and following mild myocardial infarction.
- Detection in serum requires extensive tissue damage causing catastrophic breakdown of cellular mitochondria.
- Constitutes up to of total CK activity in cardiac tissue.
- Clinical associations: Malignant tumors and severe cardiac abnormalities.
- Analytical Warning: In certain automated analytical procedures, CK-Mi may be erroneously measured as falsely high CK-MB levels.
Diagnostic Significance and Clinical Applications
Diseases of Skeletal Muscle:
- Muscular Dystrophy: Highly elevated in all forms of muscular dystrophy, especially Duchenne-type sex-linked progressive muscular dystrophy, where total CK levels may reach up to (Upper Limit of Normal).
- Neurogenic Muscle Disease: Normal serum CK activity is observed in neurogenic muscle diseases (e.g., myasthenia gravis, multiple sclerosis, poliomyelitis).
- Healthy individuals possess serum CK consisting almost exclusively of CK-MM.
- Combined injury to both skeletal muscle and heart muscle produces prominent elevations of CK-MM.
Diseases of the Heart:
- Acute Myocardial Infarction (AMI):
- Serum CK (total CK and CK-2/CK-MB) is a highly sensitive indicator of AMI.
- Unique Time Course of CK-MB in AMI:
- Levels begin to rise within post-infarction.
- Peak activity occurs at .
- Returns to baseline normal levels within .
- Total CK Elevations: Observed following cardiac trauma, including heart surgery and heart transplantation procedures.
- Non-AMI Cardiac Conditions: Elevated CK-MB activity occurs in other cardiac disorders; thus, CK-MB is not entirely specific for AMI. Diagnostic specificity increases when tested concurrently with lactate dehydrogenase (LDH).
Diseases of the Central Nervous System (CNS):
- CK-BB Isoenzyme Elevation: Observed in cerebral ischemia, cerebrovascular ischemia (where blood flow to the brain is inadequate), head injury, and acute cerebrovascular disease.
- Pediatric CNS Pathology: Elevated activity is noted in Reye's syndrome, a condition in children characterized by severe encephalopathy and liver swelling occurring as a side effect or complication of viral infections.
Diseases of the Thyroid:
- Approximately of hypothyroid subjects exhibit elevated total CK levels.
- Major isoenzyme involved in thyroid disease elevation is CK-3 (CK-MM).
- Mechanisms of CK-MM Elevation in Hypothyroidism:
- Involvement of muscle tissue secondary to increased cellular membrane permeability.
- Direct effect of thyroid hormone deficiency on enzyme expression/activity.
- Reduced clearance rate of circulating CK due to generalized hypometabolism.
CK Activity in Malignancy:
- CK-BB is rarely detected in serum under routine conditions due to its large molecular size and cellular containment.
- Massive tissue destruction or extensive damage to the brain allows leakage of CK-BB into systemic circulation.
- Serum CK-BB acts as a useful tumor marker and is associated with carcinomas of various organs, including adenocarcinoma, lung tumors, and tumors of the prostate, kidney, breast, and ovary.
Degree of CK Elevation and Differential Diagnosis
Pronounced Elevation ():
- Duchenne's muscular dystrophy
- Polymyositis
- Dermatomyositis
- Myocardial infarction
Mild or Moderate Elevation ():
- Severe physical exercise, trauma, surgical procedures
- Delirium tremens, alcoholic myopathy
- Pulmonary infarction
- Hypothyroidism
Summary of Tissue Localization and Clinical Conditions
CK-MM (CK 3):
- Primary Tissue Sources: Heart, skeletal muscle.
- Pathological and Physiological Conditions: Myocardial infarction, skeletal muscle disorders, muscular dystrophy, polymyositis, hypothyroidism, malignant hyperthermia, strenuous physical activity, intramuscular (IM) injections.
CK-MB (CK 2 - Hybrid Type):
- Primary Tissue Sources: Heart, skeletal muscle.
- Pathological Conditions: Myocardial infarction, myocardial injury, myocardial ischemia, angina, inflammatory heart disease, cardiac surgery, Duchenne-type muscular dystrophy, polymyositis, malignant hyperthermia, Reye's syndrome, Rocky Mountain spotted fever, carbon monoxide poisoning.
CK-BB (CK 1):
- Primary Tissue Sources: Brain, uterus, colon, bladder, lung, prostate, stomach, thyroid.
- Pathological Conditions: CNS shock, anoxic encephalopathy, cerebrovascular accident (stroke), severe seizures, placental or uterine trauma, systemic carcinomas, Reye's syndrome, carbon monoxide poisoning, malignant hyperthermia, acute and chronic renal failure.
Methods of Determination
- Tanzer-Gilbarg Assay:
- Methodological Basis: Forward reaction measuring the ability of CK to catalyze phosphate transfer; optimum pH ; absorbance read at .
- Interference Profile: Highly susceptible to interferences from endogenous substances across the coupled sequence.
- Reaction Scheme:
- Oliver-Rosalki Method:
- Methodological Basis: Utilizes the reverse reaction; optimum pH .
- Operational Advantages: Most commonly performed reference method; operates faster than the forward reaction, with greater overall sensitivity, specificity, and fewer chemical interferences.
- Measurement Principle: The rate of NADPH formation is directly proportional to CK enzymatic activity.
- Reaction Scheme:
Sources of Error and Reference Ranges
Adenylate Kinase (AK) Interference:
- Adenylate kinase is an erythrocyte enzyme released during sample hemolysis.
- Migration: Appears as an artifactual band cathodal to CK-MM on electrophoresis.
- Biochemical Activity: Catalyzes the reaction , directly generating ATP.
- Impact: Interferences with chemical or immunoinhibition assays, leading to falsely elevated total CK or CK-MB results.
Hemolysis Management:
- Red blood cells (RBCs) are devoid of CK activity but contain high levels of AK.
- Specimen requirement: Hemolyzed blood samples must be strictly avoided.
Reference Ranges (at ):
- Total CK (Male):
- Total CK (Female):
- CK-MB Fraction: of Total CK
Separation Techniques
Electrophoresis:
- Status: Reference method and most clinically useful separation technique.
- Visualization: Bands are visualized by incubating the support medium with a concentrated CK assay mixture utilizing the reverse reaction.
- Fluorescence Detection: Produced NADPH is detected via bluish-white fluorescence following excitation under ultraviolet (UV) light.
- Diagnostic Advantage: Allows direct visualization of adenylate kinase bands originating from hemolyzed samples, which otherwise alter ADP-to-ATP conversion rates.
Ion-Exchange Chromatography:
- Mechanism: Separation based on interaction with charged resin column beds.
- Performance: Holds potential for greater sensitivity and precision than electrophoresis when performed under precise technical conditions.
- Column Saturation / Unsatisfactory Column Errors:
- CK-MM may merge into the CK-MB fraction.
- CK-BB may co-elute alongside CK-MB.
- Macro-CK forms may co-elute alongside CK-MB.
Immunoassays:
- Mechanism: Employs specific monoclonal or polyclonal antibodies to bind target enzyme proteins.
- Performance: Reliably detects CK-2 (CK-MB) due to minimal antibody cross-reactivity.
- Analytical Focus: Measures total enzyme protein mass concentration rather than catalytic enzyme activity.
- Features: Detects enzymatically inactive CK-2; capable of detecting myocardial infarction earlier post-onset than activity-based assays.
Immunoinhibition:
- Mechanism: Specific anti-CK-M subunit antiserum is added to the patient sample to completely inhibit both M subunits of CK-MM and the single M subunit of CK-MB.
- Residual Activity: Measures the remaining uninhibited activity of the B subunit of CK-MB as well as any B subunits of CK-BB.
- Calculation: Residual activity following M-subunit inhibition is multiplied by to calculate total CK-MB activity (since of CK-MB activity is inhibited).
- Major Disadvantage: Detects active CK-BB (normally absent in serum), yielding falsely elevated CK-MB results whenever CK-BB is present.
- Interference from Atypical Forms: Atypical forms (CK-Mi and macro-CK) lack M subunits and are not inhibited by anti-M antibodies, causing erroneous overestimation of MB activity.
- Analytic Utility: Allows differentiation of true MB activity from adenylate kinase and atypical isoenzymes; highly specific analytic procedure for CK2 when no residual M-subunit activity survives inhibition.